Marketing medicines through randomised controlled trials: the case of interferon.
作者信息
Pieters T
机构信息
Section of Medical History, School of Medicine, Vrije Universiteit Amsterdam, 1081 BT Amsterdam, Netherlands.
出版信息
BMJ. 1998 Oct 31;317(7167):1231-3. doi: 10.1136/bmj.317.7167.1231.
Abstract
摘要
相似文献
1
Marketing medicines through randomised controlled trials: the case of interferon.通过随机对照试验进行药品营销：以干扰素为例。
BMJ. 1998 Oct 31;317(7167):1231-3. doi: 10.1136/bmj.317.7167.1231.
2
Trend toward noninferiority trials may mean more difficult interpretation of trial results.非劣效性试验的趋势可能意味着试验结果的解读更加困难。
J Natl Cancer Inst. 2007 Dec 5;99(23):1746-8. doi: 10.1093/jnci/djm258. Epub 2007 Nov 27.
3
[High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?].[高剂量干扰素-α与预后不良黑色素瘤的辅助治疗：药物上市许可的挽歌？]
Ann Dermatol Venereol. 1999 Mar;126(3):211-3.
4
[Marketing of the LIFE trial anticipates evaluation of the drug].
Lakartidningen. 2002 Apr 25;99(17):1964.
5
[Marketing of researchers--lack of judgment or a new trend?].[研究人员的营销——是缺乏判断力还是一种新趋势？]
Lakartidningen. 2002 Apr 25;99(17):1962-3.
6
About media, audiences and marketing medicines: the interferons.
Clio Med. 2002;66:229-43.
7
Good manners for the pharmaceutical industry.
Lancet. 1997 Jun 7;349(9066):1635.
8
Scientific imperialism.科学帝国主义
BMJ. 1997 Mar 22;314(7084):840-1. doi: 10.1136/bmj.314.7084.840.
9
The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals.从患者、公众和医疗保健专业人员角度看随机对照试验的伦理问题
BMJ. 1998 Oct 31;317(7167):1209-12. doi: 10.1136/bmj.317.7167.1209.
引用本文的文献
1
The Imperative of Regulation: The Co-creation of a Medical and Non-medical US Opioid Crisis.监管的必要性：美国医疗与非医疗阿片类药物危机的共同形成
Psychoactives. 2023 Nov 3;2(4):317-336. doi: 10.3390/psychoactives2040020.
2
How to produce 'marketable and profitable results for the company': from viral interference to Roferon A.如何为公司带来“有市场和盈利的成果”：从病毒干扰到罗扰素 A。
Hist Philos Life Sci. 2019 Jul 30;41(3):30. doi: 10.1007/s40656-019-0268-8.
3
Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.应对精准医学时代高价处方药的挑战：对药物生命周期、治疗药物市场和监管框架的系统评价
PLoS One. 2017 Aug 16;12(8):e0182613. doi: 10.1371/journal.pone.0182613. eCollection 2017.
4
Does participation in clinical trials influence the costs of future management of patients?参与临床试验是否会影响患者未来治疗管理的费用？
Eur J Health Econ. 2012 Oct;13(5):569-74. doi: 10.1007/s10198-011-0359-2. Epub 2011 Nov 10.
5
Participatory workshops are not enough to prevent policy implementation failures: an example of a policy development process concerning the drug interferon-beta for multiple sclerosis.参与式研讨会不足以防止政策实施失败：以多发性硬化症药物β-干扰素的政策制定过程为例。
Health Care Anal. 2008 Jun;16(2):161-75. doi: 10.1007/s10728-007-0069-1. Epub 2007 Oct 11.
6
Evidence-based ethics for neurology and psychiatry research.神经病学与精神病学研究的循证伦理学
NeuroRx. 2004 Jul;1(3):372-7. doi: 10.1602/neurorx.1.3.372.
7
Unbiased, relevant, and reliable assessments in health care: important progress during the past century, but plenty of scope for doing better.医疗保健中的无偏倚、相关且可靠的评估：过去一个世纪取得了重要进展，但仍有很大的改进空间。
BMJ. 1998 Oct 31;317(7167):1167-8. doi: 10.1136/bmj.317.7167.1167.
本文引用的文献
1
Use of placebo controls in clinical trials disputed.临床试验中安慰剂对照的使用存在争议。
Science. 1995 Jan 6;267(5194):25-6. doi: 10.1126/science.7809605.
2
Interferon and its first clinical trial: looking behind the scenes.干扰素及其首次临床试验：幕后探秘
Med Hist. 1993 Jul;37(3):270-95. doi: 10.1017/s0025727300058452.
3
Interferon: decline and stall.
Nature. 1981 May 14;291(5811):105-6. doi: 10.1038/291105a0.
4
Interferon: no magic bullet against cancer.
Science. 1981 Apr 10;212(4491):141-2. doi: 10.1126/science.6163213.
5
Interferon: cloudy but intriguing future.
JAMA. 1981 Jan 9;245(2):109-10, 115-6.
6
Biological response modifiers.
Semin Oncol. 1986 Jun;13(2):131-258.
Zotero 插件